Free Trial
NASDAQ:RPTX

Repare Therapeutics Q3 2024 Earnings Report

Repare Therapeutics logo
$1.40 +0.01 (+0.72%)
As of 09:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Repare Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.83
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Repare Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.37 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Repare Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Repare Therapeutics Earnings Headlines

Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
See More Repare Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Repare Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Repare Therapeutics and other key companies, straight to your email.

About Repare Therapeutics

Repare Therapeutics (NASDAQ:RPTX), a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

View Repare Therapeutics Profile

More Earnings Resources from MarketBeat